Country for PR: Japan
Contributor: Kyodo News JBN
Thursday, July 12 2018 - 15:00
AsiaNet
AGC to Expand GMP-Compliant Synthetic Pharmaceutical Intermediate and Active Ingredient Production Capacity Tenfold
TOKYO, July 12, 2018 /Kyodo JBN-AsiaNet/--

- Broadened CDMO Business Will Cover Commercial New Drugs As Well As in 
Development Stage of Ones -

AGC Inc., a world-leading manufacturer of glass, chemicals and high-tech 
materials, announced on July 12 a major expansion of facilities at its Chiba 
Plant that will result in an approximately tenfold increase in the company's 
GMP(*1)-compliant synthetic pharmaceutical intermediate and active ingredient 
(*2) production capacity. The new capacity is set to come online in October 
2019.

AGC began developing and manufacturing pharmaceutical and agrochemical 
intermediates and active ingredients on a contract basis in the 1980s. 
Leveraging its edge in fluorine technologies and extensive experience in 
in-house drug discovery and other fields, AGC now offers a range of CDMO (*3) 
services tailored to customer needs.

While AGC has to date mainly provided CDMO services for in the development 
stage of new drugs, this expansion will give AGC the end-to-end capability to 
produce commercial drugs too, allowing it to deliver more advanced one-stop 
solutions. The new facilities will also be capable of producing hard-to-handle 
active ingredients, such as the highly potent active pharmaceutical ingredients 
typically used in cancer therapy. AGC will therefore be able to meet a wider 
range of customer demand.

The AGC Group's "AGC plus" management policy identifies the life sciences as 
one of its strategic businesses. Moving forward, the group will continue to 
invest in the capacity needed to meet ongoing growth in demand for 
pharmaceutical intermediate and active ingredient CDMO services.

(*1) GMP: Good manufacturing practice (standards governing the production and 
quality control of pharmaceutical products and quasi-drugs).

(*2) Synthetic pharmaceutical intermediates and active ingredients: 
Intermediates and active ingredients for pharmaceutical products that are 
produced by chemical synthesis.

(*3) CDMO: Contract development and manufacturing organization (a company that 
develops production methods and manufactures products for another company on a 
contract basis).

For more information, please visit: 
https://kyodonewsprwire.jp/attach/201807095798-O1-vIa55jNK.pdf

About the AGC Group
AGC Inc. (Headquarters: Tokyo, President & CEO: Takuya Shimamura) is the parent 
company of the AGC Group, a world-leading glass solution provider and supplier 
of flat, automotive and display glass, chemicals, ceramics and other high-tech 
materials and components. Based on more than a century of technical innovation, 
the AGC Group has developed a wide range of cutting-edge products. The AGC 
Group employs some 50,000 people worldwide and generates annual sales of 
approximately 1.5 trillion Japanese yen through business in about 30 countries. 
For more information, please visit: http://www.agc.com/en/.

* The company changed its name from Asahi Glass Co., Ltd. to AGC Inc. on July 
1, 2018.


Source: AGC Inc.